This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

TIDES Asia: Oligonucleotide & Peptide Therapeutics Scientific Forum

EARLY SAVINGS DEADLINE EXPIRES IN:

  • 00
    Days
  • 00
    Hrs
  • 00
    Mins
  • 00
    Secs
7-9 March 2023
Westin Miyako KyotoKyoto, Japan

Vasant Jadhav, PhD
Senior Vice President, Head of RNAi Platform at Alnylam Pharmaceuticals

Profile

Vasant Jadhav is a Senior Vice President of Research at Alnylam Pharmaceuticals, where he leads the Alnylam Technology group responsible for siRNA designs, new applications and delivery solutions that have led to 5 approved drugs and deep pipeline across multiple tissue targets. Prior to Alnylam, Vasant was at Sirna/Merck for 12 years and worked on optimizing siRNA chemical modifications and leading the efforts on conjugate delivery approach. He obtained his PhD in Biotechnology from the University of Pune in 1998 and post-doctoral fellowship at University of Colorado, Boulder working on ribozymes. Dr. Jadhav has authored >30 peer-reviewed publication in the field of nucleic acids therapeutics.

Agenda Sessions

  • RNAi in the Era of Nucleic Acid-based Therapeutics

    4:00pm

Speakers at this event